| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Medicine and Microbiology-Immunology, University of California Medical Center, San Francisco, California 94143-0711, USA
1Correspondence: University of California, UB8B, Box 0711, 533 Parnassus at 4th, San Francisco, CA 94143-0711, USA. E-mail : egoetzl{at}itsa.ucsf.edu
Vasoactive intestinal peptide (VIP) and its G-protein-coupled receptors (VPAC1 and VPAC2 Rs) are prominent in the immune system. In T cells, VPAC1 R is expressed constitutively whereas VPAC2 R is induced only after stimulation of the T cell receptor (TCR) or exposure to some cytokines. VPAC1 R and VPAC2 R also transduce different effects of VIP on T cells. Constitutive expression of VPAC2 R selectively in CD4+ T cells (helper-inducer Th cells) of transgenic (TG) C57BL/6 mice directed by the lck tyrosine kinase promoter is now shown to evoke production of more Th2-type interleukins 4 and 5, and less Th1-type interferon 
after TCR activation. VPAC2 R TG mice consequently have significant elevations of blood IgE, IgG1, and eosinophils. VPAC2 R TG mice also show increased IgE antibody responses, which mediate heightened cutaneous allergic reactions, and have depressed delayed-type hypersensitivity. VIP enhancement of the ratio of Th2 cell to Th1 cell cytokines thus evokes an allergic state in normally nonallergic mice, which suggests the possibility of neuropeptide contributions to immune phenotypic alterations in human hypersensitivity diseases.—Voice, J. K., Dorsam, G., Lee, H., Kong, Y., Goetzl, E. J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.
Key Words: neuropeptide • IgE • cytokines • eosinophils • hypersensitivity
This article has been cited by other articles:
|
|
 |
|
  E. Gonzalez-Rey, P. Anderson, and M. Delgado Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Szema, S. A. Hamidi, S. Lyubsky, K. G. Dickman, S. Mathew, T. Abdel-Razek, J. J. Chen, J. A. Waschek, and S. I. Said Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L880 - L886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Huang, A. L. Miller, W. Wang, Y. Kong, S. Paul, and E. J. Goetzl Differential Signaling of T Cell Generation of IL-4 by Wild-Type and Short-Deletion Variant of Type 2 G Protein-Coupled Receptor for Vasoactive Intestinal Peptide (VPAC2). J. Immunol., June 1, 2006; 176(11): 6640 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sharma, M. Delgado, and D. Ganea Granzyme B, a New Player in Activation-Induced Cell Death, Is Down-Regulated by Vasoactive Intestinal Peptide in Th2 but Not Th1 Effectors J. Immunol., January 1, 2006; 176(1): 97 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Miotto, P. Boschetto, I. Bononi, E. Zeni, G. Cavallesco, L.M. Fabbri, and C.E. Mapp Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Eur. Respir. J., December 1, 2004; 24(6): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grinninger, W. Wang, K. B. Oskoui, J. K. Voice, and E. J. Goetzl A Natural Variant Type II G Protein-coupled Receptor for Vasoactive Intestinal Peptide with Altered Function J. Biol. Chem., September 24, 2004; 279(39): 40259 - 40262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Voice, S. Donnelly, G. Dorsam, G. Dolganov, S. Paul, and E. J. Goetzl c-Maf and JunB Mediation of Th2 Differentiation Induced by the Type 2 G Protein-Coupled Receptor (VPAC2) for Vasoactive Intestinal Peptide J. Immunol., June 15, 2004; 172(12): 7289 - 7296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delgado, A. Reduta, V. Sharma, and D. Ganea VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells J. Leukoc. Biol., June 1, 2004; 75(6): 1122 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. BANGALE, S. KARLE, S. PLANQUE, Y.-X. ZHOU, H. TAGUCHI, Y. NISHIYAMA, L. LI, R. KALAGA, and S. PAUL VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease FASEB J, April 1, 2003; 17(6): 628 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Voice, C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E. J. Goetzl Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice J. Immunol., January 1, 2003; 170(1): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ganea and M. Delgado VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY Critical Reviews in Oral Biology & Medicine, May 1, 2002; 13(3): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
